MTHFR Genetics UK (Lab)

mthfr-genetics.co.uk

We are all about empowering you, in knowledge about your body's biochemistry. Right down to the level of your genetics, and encouraging you to take a proactive approach to improving your health. This can be accomplished by applying lifestyle changes and reducing exposure to environmental factors, that may contribute to, or cause your genetic mutations to start expressing, causing a decline in your health as a result.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

BIO DETECTION K9 DEVELOPS CUTTING-EDGE DETECTION FOR GRAPE VIRUS DISEASES

Bio Detection K9 | May 19, 2022

news image

Bio Detection K9 (BDK9) is pleased to announce its upcoming detection service for Leafroll and Red Blotch Virus in grapes. Of the 86 different viruses known to infect vineyards, Leafroll 3 and Red Blotch virus are among the most prevalent. These pathogens can infect all wine, table and rootstock grapes. They occur in grape production areas around the world and are responsible for causing over 70 billion dollars of damage in the United States alone. To combat these insidious diseas...

Read More

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More

RESEARCH

MAXCYTE SIGNS CLINICAL AND COMMERCIAL LICENSE WITH SANA BIOTECHNOLOGY

Maxcyte, Inc. | August 12, 2021

news image

MaxCyte, Inc., a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines. Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitle...

Read More

HALO LABS LAUNCHED AGGREGATE AND PARTICLE ID, CALLED AURA FOR BIOTHERAPEUTIC DEVELOPMENT

Halo Labs | June 29, 2020

news image

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.Aura is the next generation of the Horizon®, Halo Labs' popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3x106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The...

Read More
news image

MEDICAL

BIO DETECTION K9 DEVELOPS CUTTING-EDGE DETECTION FOR GRAPE VIRUS DISEASES

Bio Detection K9 | May 19, 2022

Bio Detection K9 (BDK9) is pleased to announce its upcoming detection service for Leafroll and Red Blotch Virus in grapes. Of the 86 different viruses known to infect vineyards, Leafroll 3 and Red Blotch virus are among the most prevalent. These pathogens can infect all wine, table and rootstock grapes. They occur in grape production areas around the world and are responsible for causing over 70 billion dollars of damage in the United States alone. To combat these insidious diseas...

Read More
news image

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More
news image

RESEARCH

MAXCYTE SIGNS CLINICAL AND COMMERCIAL LICENSE WITH SANA BIOTECHNOLOGY

Maxcyte, Inc. | August 12, 2021

MaxCyte, Inc., a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines. Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitle...

Read More
news image

HALO LABS LAUNCHED AGGREGATE AND PARTICLE ID, CALLED AURA FOR BIOTHERAPEUTIC DEVELOPMENT

Halo Labs | June 29, 2020

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.Aura is the next generation of the Horizon®, Halo Labs' popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3x106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The...

Read More